Pleco Therapeutics' aim is to establish the market value and therapeutic potential of our patented PlecoidTM medications by focusing first on orphan cancer treatments. Current pre-clinical development activities at the firm are focused on the development of medicines for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, andSmall-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.

Clinical Trials

Health Care

Pharmaceutical

Pleco Therapeutics BV

Org chart

Teams

Offices

Similar companies